KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

Blood

Volumn 119, Issue 6, 2012, Pages 1511-1521

  Zhao, Ling ^a   Melenhorst, Jan J ^b   Alemu, Lemlem ^a   Kirby, Martha ^a   Anderson, Stacie ^a   Kench, Maggie ^a   Hoogstraten Miller, Shelley ^a   Brinster, Lauren ^c   Kamikubo, Yasuhiko ^a,e   Gilliland, D Gary ^d,f   Liu, P Paul ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c Office of the Director   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBFB MYH11 FUSION PROTEIN; HYBRID PROTEIN; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSDUCTION; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84863418375     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-338210     Document Type: Article

References (50)

1. Dunphy CH. Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. J Clin Lab Anal. 1999;13(1):19-26. (Pubitemid 29053196)
2. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261(5124):1041-1044. (Pubitemid 23300863)
3. Castilla LH, Garrett L, Adya N, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet. 1999;23(2):144-146. (Pubitemid 29455384)
4. Castilla LH, Perrat P, Martinez NJ, et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2004;101(14):4924-4929. (Pubitemid 38469179)
5. Valk PJ, Bowen DT, Frew ME, Goodeve AC, Lowenberg B, Reilly JT. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). Haematologica. 2004; 89(1):106. (Pubitemid 38165863)
6. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-KIT, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006; 20(6):965-970. (Pubitemid 43797286)
7. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775-777. (Pubitemid 36718195)
8. Kim HG, Kojima K, Swindle CS, et al. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood. 2008;111(3): 1567-1574. (Pubitemid 351213447)
9. Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2003;100(16):9506-9511. (Pubitemid 37033958)
10. Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2008;22(2):303-307.
11. Edling CE, Hallberg B. c-KIT-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39(11):1995-1998. (Pubitemid 47376824)
12. Kissel H, Timokhina I, Hardy MP, et al. Point mutation in KIT receptor tyrosine kinase reveals essential roles for KIT signaling in spermatogenesis and oogenesis without affecting other KIT responses. EMBO J. 2000;19(6):1312-1326. (Pubitemid 30151027)
13. Spritz RA, Giebel LB, Holmes SA. Dominant negative and loss of function mutations of the c- KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Am J Hum Genet. 1992;50(2):261-269.
14. Hirota S, Isozaki K, Moriyama Y, et al. Gain-offunction mutations of c-KIT in human gastrointestinal stromal tumors. Science. 1998;279(5350): 577-580. (Pubitemid 28067289)
15. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-KIT in acute myeloblastic leukemia cells. Blood. 1991; 78(11):2962-2968.
16. Kita K, Shirakawa S, Kamada N. Cellular characteristics of acute myeloblastic leukemia associated with t(8;21)(q22;q22). The Japanese Cooperative Group of Leukemia/Lymphoma. Leuk Lymphoma. 1994;13(3-4):229-234. (Pubitemid 24141329)
17. Osato M, Asou N, Okubo T, et al. Myelomonoblastic leukaemia cells carrying the PEBP2beta/ MYH11 fusion gene are CD34, c-KIT+ immature cells. Br J Haematol. 1997;97(3):656-658. (Pubitemid 27261635)
18. Müller AM, Duque J, Shizuru JA, Lubbert M. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene. 2008;27(44):5759-5773.
19. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89(8):920-925. (Pubitemid 39049899)
20. Gari M, Goodeve A, Wilson G, et al. c-KIT protooncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999;105(4):894-900. (Pubitemid 29309094)
21. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911. (Pubitemid 46630738)
22. Beghini A, Peterlongo P, Ripamonti CB, et al. CKIT mutations in core binding factor leukemias. Blood. 2000;95(2):726-727. (Pubitemid 30041697)
23. Kohl TM, Schnittger S, Ellwart JW, Hiddemann W, Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood. 2005; 105(8):3319-3321.
24. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the protooncogene c-KIT in a human mast cell leukemia cell line causing ligand-independent activation of c-KIT product. J Clin Invest. 1993;92(4):1736-1744. (Pubitemid 23304537)
25. Schnittger S, Kohl TM, Haferlach T, et al. KITD816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-1799. (Pubitemid 43289355)
26. Marková J, Trnková Z, Michková P, et al. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leuk Lymphoma. 2009; 50(9):1448-1460.
27. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741-1744. (Pubitemid 34533049)
28. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106(2):721-724. (Pubitemid 40981272)
29. Cairoli R, Beghini A, Morello E, et al. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. Leuk Res. 2005;29(4):397-400. (Pubitemid 40255813)
30. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107(2):752-759. (Pubitemid 43076402)
31. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865-2870. (Pubitemid 41510766)
32. Kuo YH, Landrette SF, Heilman SA, et al. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell. 2006;9(1):57-68. (Pubitemid 43069511)
33. Markowitz DG, Goff SP, Bank A. Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments. Trans Assoc Am Physicians. 1988;101:212-218.
34. Gallardo HF, Tan C, Ory D, Sadelain M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood. 1997;90(3):952-957. (Pubitemid 27314127)
35. Zhao L, Cannons JL, Anderson S, et al. CBFBMYH11 hinders early T-cell development and induces massive cell death in the thymus. Blood. 2007;109(8):3432-3440. (Pubitemid 46572533)
36. Kent D, Copley M, Benz C, Dykstra B, Bowie M, Eaves C. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin Cancer Res. 2008;14(7):1926-1930. (Pubitemid 351551100)
37. Masson K, Ronnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-KIT and Flt3. Cell Signal. 2009;21(12):1717-1726.
38. Cairoli R, Grillo G, Beghini A, et al. C-KIT point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. Leukemia. 2003;17(2):471-472. (Pubitemid 36266930)
39. Goemans BF, Zwaan CM, Cloos J, et al. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leuk Res. 2010;34(10):1302-1307.
40. Jiao B, Wu CF, Liang Y, et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia. 2009; 23(9):1598-1604.
41. Agaimy A, Dirnhofer S,Wunsch PH, Terracciano LM, Tornillo L, Bihl MP. Multiple sporadic gastrointestinal stromal tumors (GISTs) of the proximal stomach are caused by different somatic KIT mutations suggesting a field effect. Am J Surg Pathol. 2008;32(10):1553-1559.
42. Eroǧlu A, Sari A. Expression of c-KIT protooncogene product in breast cancer tissues. Med Oncol. 2007;24(2):169-174. (Pubitemid 350135967)
43. Yaren A, Oztop I, Kargi A, et al. Bax, bcl-2 and c-KIT expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract. 2006;60(6):675-682. (Pubitemid 43811647)
44. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-3468.
45. Smith MA, Pallister CJ, Smith JG. Stem cell factor: biology and relevance to clinical practice. Acta Haematol. 2001;105(3):143-150. (Pubitemid 32679596)
46. Levina V, Marrangoni A, Wang T, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-KIT autocrine signaling loop. Cancer Res. 2010;70(1):338-346.
47. Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol. 2007;27(1):267-282. (Pubitemid 46013250)
48. Wang YY, Zhao LJ, Wu CF, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2011;108(6):2450-2455.
49. Pedersen M, Ronnstrand L, Sun J. The c-KIT/ D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-KIT. Cell Signal. 2009; 21(3):413-418.
50. Mayerhofer M, Gleixner KV, Hoelbl A, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol. 2008;180(8):5466-5476.